GUIDED THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations
GUIDED THERAPEUTICS, INC. (GTHP) reported Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations of 900.00 thousand shares for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-15.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations · last filed 2026-05-15
- GUIDED THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, forfeitures and expirations for the quarter ending 2026-03-31 was 900.00K shares.
- GUIDED THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, forfeitures and expirations for the quarter ending 2024-12-31 was 0.00 shares.
- GUIDED THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, forfeitures and expirations for the quarter ending 2024-09-30 was 800.00K shares, a 1094.03% increase year-over-year.
- GUIDED THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, forfeitures and expirations for the quarter ending 2024-06-30 was 565.50K shares, a 72.66% decline year-over-year.
- GUIDED THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, forfeitures and expirations for fiscal 2024 was 1.56M shares, a 83.64% decline from fiscal 2023.
- GUIDED THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, forfeitures and expirations for fiscal 2023 was 9.55M shares, a 114.46% increase from fiscal 2022.
- GUIDED THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, forfeitures and expirations for fiscal 2022 was 4.45M shares, a 157.33% increase from fiscal 2021.
- GUIDED THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, forfeitures and expirations for fiscal 2021 was 1.73M shares, a 2470845.71% increase from fiscal 2020.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations 12 month |
|---|---|---|---|---|
| 2026-03-31 | 900.00K shares 10-Q · filed 2026-05-15 | |||
| 2024-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | 800.00K shares derived: sum of 2 quarters · filed 2026-03-31 | 1.37M shares derived: sum of 3 quarters · filed 2026-03-31 | 1.56M shares 10-K · filed 2026-03-31 |
| 2024-09-30 | 800.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | 1.37M shares derived: sum of 2 quarters · filed 2025-11-13 | 1.56M shares 10-Q · filed 2025-11-13 | 1.56M shares derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | 565.50K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | 761.50K shares 10-Q · filed 2025-08-14 | 761.50K shares derived: sum of 3 quarters · filed 2025-08-14 | 828.50K shares derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | 196.00K shares 10-Q · filed 2025-05-15 | 196.00K shares derived: sum of 2 quarters · filed 2025-05-15 | 263.00K shares derived: sum of 3 quarters · filed 2025-05-15 | 2.33M shares derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | 67.00K shares derived: sum of 2 quarters · filed 2025-03-31 | 2.14M shares derived: sum of 3 quarters · filed 2025-03-31 | 9.55M shares 10-K · filed 2025-03-31 |
| 2023-09-30 | 67.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | 2.14M shares derived: sum of 2 quarters · filed 2024-11-14 | 9.55M shares 10-Q · filed 2024-11-14 | |
| 2023-06-30 | 2.07M shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | 9.48M shares 10-Q · filed 2024-08-14 | ||
| 2023-03-31 | 7.41M shares 10-Q · filed 2024-05-14 | |||
| 2022-12-31 | 4.45M shares 10-K · filed 2024-03-28 | |||
| 2021-12-31 | 1.73M shares 10-K · filed 2023-03-30 | |||
| 2021-06-30 | 400.00 shares derived: 10-Q 6 month − 10-Q/A 3 month · filed 2021-08-18 | 1.73M shares 10-Q · filed 2021-08-18 | 1.73M shares derived: sum of 3 quarters · filed 2022-03-30 | 1.73M shares derived: sum of 4 quarters · filed 2022-03-30 |
| 2021-03-31 | 1.73M shares 10-Q/A · filed 2021-08-18 | 1.73M shares derived: sum of 2 quarters · filed 2022-03-30 | 1.73M shares derived: sum of 3 quarters · filed 2022-03-30 | 1.73M shares derived: sum of 4 quarters · filed 2022-03-30 |
| 2020-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q/A 9 month · filed 2022-03-30 | 0.00 shares derived: sum of 2 quarters · filed 2022-03-30 | 0.00 shares derived: sum of 3 quarters · filed 2022-03-30 | 70.00 shares 10-K · filed 2022-03-30 |
| 2020-09-30 | 0.00 shares derived: 10-Q/A 9 month − 10-Q 6 month · filed 2020-11-05 | 0.00 shares derived: sum of 2 quarters · filed 2020-11-05 | 70.00 shares 10-Q/A · filed 2020-11-05 | |
| 2020-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-20 | 70.00 shares 10-Q · filed 2020-08-20 | ||
| 2020-03-31 | 70.00 shares 10-Q · filed 2020-07-07 |